{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T07:52:46Z","timestamp":1648626766791},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.patbio.2006.10.002","type":"journal-article","created":{"date-parts":[[2006,11,30]],"date-time":"2006-11-30T15:10:51Z","timestamp":1164899451000},"page":"242-245","source":"Crossref","is-referenced-by-count":0,"title":["FIP1L1\u2013PDGFRA positive chronic eosinophilic leukemia in\u00a0Tunisian patients"],"prefix":"10.1016","volume":"55","author":[{"given":"S.","family":"Menif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Omri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hafsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ben Romdhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Turki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Meddeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Dellagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.patbio.2006.10.002_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L\u2013PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long term experience with imatinib therapy, and a clinical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.patbio.2006.10.002_bib2","first-page":"2","article-title":"Eosinophilic leukemias and the idiopathic hypereosinophilic syndrome","volume":"95","author":"Bain","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.patbio.2006.10.002_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2141.2003.04458.x","article-title":"Cytogenetic and molecular genetic aspects of eosinophilic leukemias","volume":"122","author":"Bain","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.patbio.2006.10.002_bib4","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A Tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.patbio.2006.10.002_bib5","first-page":"596","article-title":"The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del (4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases","volume":"90","author":"La Starza","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.patbio.2006.10.002_bib6","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1\u2013PDGFR\u03b1 fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2006.10.002_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1\u2013PDGFRA(+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.patbio.2006.10.002_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.beha.2005.07.013","article-title":"Eosinophilic disorders: molecular pathogenesis, new classification and modern therapy","volume":"19","author":"Gotlib","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.patbio.2006.10.002_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet derived growth factor receptor","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol."},{"key":"10.1016\/j.patbio.2006.10.002_bib10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2006.10.002_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.patbio.2006.10.002_bib12","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2006.10.002_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-005-1084-7","article-title":"Imatinib mesylateas a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature","volume":"85","author":"Muller","year":"2006","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.patbio.2006.10.002_bib14","first-page":"9","article-title":"Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate","volume":"3","author":"Schaller","year":"2001","journal-title":"MedGenMed"},{"key":"10.1016\/j.patbio.2006.10.002_bib15","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811406001957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811406001957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T06:58:59Z","timestamp":1547189939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811406001957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0369811406001957"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2006.10.002","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}